WASHINGTON — Florida governor and presidential hopeful Ron DeSantis has ballyhooed a high-profile plan to import prescription drugs from Canada, even suing the Biden administration for allegedly holding up a necessary sign-off.
But the plan’s long odds just got longer: the Food and Drug Administration said in a letter last week that Florida’s plan has gaping holes — and the state has less than a week to explain how it’ll fix them.
The FDA “identified several deficiencies,” in the drug-import plan, it said. Despite its thousands of pages, the plan does not show whether it meets the two overarching requirements of saving money and securing the drug supply chain, the agency explained. The FDA gave the state until August 28 to flesh out those two subjects.
This article is exclusive to STAT+ subscribers
Unlock this article — plus daily intelligence on Capitol Hill and the life sciences industry — by subscribing to STAT+.
Already have an account? Log in
Already have an account? Log in
About the Author Reprints
To submit a correction request, please visit our Contact Us page.
STAT encourages you to share your voice. We welcome your commentary, criticism, and expertise on our subscriber-only platform, STAT+ Connect